Empagliflozin/linagliptin/metformin

Empagliflozin/linagliptin/metformin
Combination of
EmpagliflozinSGLT2 inhibitor
LinagliptinDPP-4 inhibitor
MetforminAnti-diabetic biguanide
Clinical data
Trade namesTrijardy XR
AHFS/Drugs.comProfessional Drug Facts
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
KEGG

Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a fixed-dose combination medication used for the treatment of type 2 diabetes.[2] It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.[3][4]

  1. ^ "Trijardy XR- empagliflozin, linagliptin, metformin hydrochloride tablet, extended release". DailyMed. Archived from the original on 25 December 2021. Retrieved 24 December 2021.
  2. ^ Kim ES, Deeks ED (September 2015). "Empagliflozin/Linagliptin: A Review in Type 2 Diabetes". Drugs. 75 (13): 1547–57. doi:10.1007/s40265-015-0457-z. PMID 26323340. S2CID 27675087.
  3. ^ "Trijardy XR: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 23 May 2020. Retrieved 11 February 2020.
  4. ^ "US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes" (Press release). Eli Lilly and Company. 27 January 2020. Archived from the original on 13 February 2020. Retrieved 10 February 2020 – via PR Newswire.